BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 84.32% | -497.78% | -206.70% | -72.26% | -- |
| Total Depreciation and Amortization | 47,775.00% | 72,416.67% | 16,575.00% | 0.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00% | -- |
| Total Other Non-Cash Items | -111.64% | -- | -- | 14,994.44% | -- |
| Change in Net Operating Assets | 1,102.44% | 351.00% | 294.13% | -76.70% | -- |
| Cash from Operations | 88.99% | 50.86% | 110.96% | -50.58% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 567.27% | -- |
| Total Debt Issued | -20.22% | -25,587.50% | 79,587.50% | 100.78% | -- |
| Total Debt Repaid | 43.72% | 1,650.00% | 47.11% | 20,700.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -1,744.12% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.03% | -4,640.56% | 11,365.64% | 60.77% | -- |
| Foreign Exchange rate Adjustments | -- | -96.64% | -79.17% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.59% | 74.65% | 93.31% | -16.48% | -- |
